Kinase Targets and Drug Discovery
- 1st Edition - June 1, 2026
- Latest edition
- Editor: Xiaoyun Lu
- Language: English
Kinase Targets and Drug Discovery covers the critical role of kinases as regulators of cellular functions and their implications in a range of diseases, from cancers to cardio… Read more
Kinase Targets and Drug Discovery covers the critical role of kinases as regulators of cellular functions and their implications in a range of diseases, from cancers to cardiovascular disorders and inflammatory conditions. Readers will explore foundational concepts on the functions of kinases, the role of kinase inhibitors in disease therapy, and challenges faced. The second section focuses on innovative strategies in kinase drug discovery, covering screening and computational approaches, along with the development of covalent, macrocyclic, allosteric inhibitors, and kinase degraders. Final sections examine clinical applications, detailing how kinase inhibition can be harnessed for cancer therapies, non-oncologic diseases, and even non-catalytic functions.
This book will serve as an indispensable resource for pharmacologists, medicinal chemists, and researchers in both academia and industry. By bridging the gap between foundational research and clinical application, it equips professionals with the latest insights and practical approaches to advance their understanding to contribute meaningfully to the evolving landscape of drug discovery.
This book will serve as an indispensable resource for pharmacologists, medicinal chemists, and researchers in both academia and industry. By bridging the gap between foundational research and clinical application, it equips professionals with the latest insights and practical approaches to advance their understanding to contribute meaningfully to the evolving landscape of drug discovery.
- Provides a comprehensive overview of kinase biology and its therapeutic implications across various diseases
- Explores innovative strategies for kinase inhibitor discovery and development
- Includes insights into cutting-edge technologies such as AI and novel therapeutic modalities
- Covers practical approaches for researchers in academia and industry to enhance drug discovery efforts
- Serves as an essential resource for understanding the clinical applications of kinase inhibitors in modern therapeutics
Academic scholars and research professionals focused on drug discovery and development
Part I: Kinase as drug target: An overview
1. Introduction to Kinases and Their Functions
2. Kinase Inhibitors in Diseases Therapy
3. Challenges in Kinase Inhibitors Discovery
Part II: Strategies in Kinase Drug Discovery
4. Screening Approaches for Kinases
5. Computational Approaches for Kinases
6. Covalent Inhibitors of Kinase
7. Macrocyclic Inhibitors of Kinase
8. Allosteric Inhibitors of Kinase
9. Kinase Degraders
10. Kinase Activators
Part III: Clinical Indications for Kinase Inhibitors
11. Kinase Inhibition for Cancer (Contain Immuno-Oncology)
12. Kinase Inhibition for Nononcologic Diseases
13. Kinase Inhibition for Non-Catalytic Function
1. Introduction to Kinases and Their Functions
2. Kinase Inhibitors in Diseases Therapy
3. Challenges in Kinase Inhibitors Discovery
Part II: Strategies in Kinase Drug Discovery
4. Screening Approaches for Kinases
5. Computational Approaches for Kinases
6. Covalent Inhibitors of Kinase
7. Macrocyclic Inhibitors of Kinase
8. Allosteric Inhibitors of Kinase
9. Kinase Degraders
10. Kinase Activators
Part III: Clinical Indications for Kinase Inhibitors
11. Kinase Inhibition for Cancer (Contain Immuno-Oncology)
12. Kinase Inhibition for Nononcologic Diseases
13. Kinase Inhibition for Non-Catalytic Function
- Edition: 1
- Latest edition
- Published: June 1, 2026
- Language: English
XL
Xiaoyun Lu
Xiaoyun Lu studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working for six years in Guangzhou Institutes of Biomedicine and Health (GIBH), she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of new generation of kinase inhibitors to overcome clinical resistance of cancers. She has been involved in the design and development of EGFR, DDRs, FGFR4, and TRKs inhibitors. Among them, two drug-like inhibitors of kinase have been into clinic. She has published about 100 SCI papers and co-invented 40 patents, received the Special Professor of Changjiang Scholars of Ministry of Education (2024), the National Outstanding Youth Fund (2019), China Pharmaceutical Association - Servier Pharmaceutical Chemistry Award (2014) and Chinese Academy of Sciences Lu Jiaxi Young Talent Award (2015). She currently serves as editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, etc.
Affiliations and expertise
Jinan University, China